Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis

Autor:	Jorge I. Gamez-Nava, Esther N Sanchez-Rodriguez, José Francisco Muñoz-Valle, Sergio Ramón Gutiérrez-Ureña, José Clemente Vásquez-Jiménez, Sergio Cerpa-Cruz, N. A. Rodriguez-Jimenez, Erika Anita Aguilar-Chavez, M. L. Vazquez-Villegas, Laura Gonzalez-Lopez, Edsaul Emilio Perez-Guerrero, Ana Miriam Saldaña-Cruz, N. S. Fajardo-Robledo, Ernesto Germán Cardona-Muñoz, M. Ramirez-Villafaña
Rok vydání:	2018
Předmět:	musculoskeletal diseases 0301 basic medicine Allergy medicine.medical_specialty Immunology Drug resistance Logistic regression Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Pharmacology (medical) skin and connective tissue diseases Prospective cohort study P-glycoprotein 030203 arthritis & rheumatology Pharmacology biology business.industry Confounding medicine.disease Rheumatology 030104 developmental biology Rheumatoid arthritis biology.protein business
Zdroj:	Inflammopharmacology. 26:1375-1381
ISSN:	1568-5608 0925-4692
Popis:	To evaluate the utility of elevated serum P-glycoprotein (P-gp) as a risk marker of therapeutic response failure in rheumatoid arthritis (RA) patients treated with disease-modifying antirheumatic drugs (DMARDs). A cross-sectional study was conducted in 151 RA patients. Patients were classified into two groups according to the response achieved in terms of the disease activity score (DAS)28 after ≥ 6 months: (1) patients with a therapeutic response to DMARDs, with DAS28
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2ae99e154883840244bb700d585c33a https://doi.org/10.1007/s10787-018-0529-2 Zobrazit plný text záznamu Full text from SpringerLink